Review



atac sequencing atacseq  (Zymo Research)


Bioz Verified Symbol Zymo Research is a verified supplier
Bioz Manufacturer Symbol Zymo Research manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Zymo Research atac sequencing atacseq
    Development of recurrent mutations after drug treatments. A. The number of mutations in three parallel subclones following development of resistance to Dox. The number of mutations common to all three subclones (red), common to two out of three subclones (green) and mutations unique for each subclone (blue). B. A scheme showing that generation of mutations common between clones cannot occur during the propagation of the parental clone. See explanation in the text. C.Example of the lack of enrichment of mutations in open chromatin. Open chromatin assessed by <t>ATACseq</t> is shown in the lane with blue peaks, positions of mutations are shown in the lane with red bars. Data analysis in this experiment is shown in Table S2. C. Overlap of mutations between GDR and Lorlatinib. D. Overlap of mutations between osimertinib and Doxorubicin. E. Overlap of mutations between two independent lorlatinib-treated samples and one crizotinib-treated sample. F. Computer simulation of random generation of osimertinib-induced mutations. Observed number of common mutations is shown as red line. Random sampling of mutations and their overlap (100,000 pairs) is shown as blue lines. G. Overlap of mutations between osimertinib day 21 (0SM-3T) and osimertinib subclone 1 samples (OSM-1CL). H. Overlap of mutations between osimertinib day 21 (0SM-3T) and osimertinib mutations common between three subclones (OSM-TRPL).
    Atac Sequencing Atacseq, supplied by Zymo Research, used in various techniques. Bioz Stars score: 95/100, based on 73 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/atac+sequencing+atacseq/ATAC-Seq/bio_rxiv__64898__2026__02__20__707073-327-2-8
    Average 95 stars, based on 73 article reviews
    atac sequencing atacseq - by Bioz Stars, 2026-08
    95/100 stars

    Images

    1) Product Images from "Mega-frequency mutagenesis: generation of non-random precise mutations with extremely high frequency upon adaptation of cancer cells to drugs and stress"

    Article Title: Mega-frequency mutagenesis: generation of non-random precise mutations with extremely high frequency upon adaptation of cancer cells to drugs and stress

    Journal: bioRxiv

    doi: 10.64898/2026.02.20.707073

    Development of recurrent mutations after drug treatments. A. The number of mutations in three parallel subclones following development of resistance to Dox. The number of mutations common to all three subclones (red), common to two out of three subclones (green) and mutations unique for each subclone (blue). B. A scheme showing that generation of mutations common between clones cannot occur during the propagation of the parental clone. See explanation in the text. C.Example of the lack of enrichment of mutations in open chromatin. Open chromatin assessed by ATACseq is shown in the lane with blue peaks, positions of mutations are shown in the lane with red bars. Data analysis in this experiment is shown in Table S2. C. Overlap of mutations between GDR and Lorlatinib. D. Overlap of mutations between osimertinib and Doxorubicin. E. Overlap of mutations between two independent lorlatinib-treated samples and one crizotinib-treated sample. F. Computer simulation of random generation of osimertinib-induced mutations. Observed number of common mutations is shown as red line. Random sampling of mutations and their overlap (100,000 pairs) is shown as blue lines. G. Overlap of mutations between osimertinib day 21 (0SM-3T) and osimertinib subclone 1 samples (OSM-1CL). H. Overlap of mutations between osimertinib day 21 (0SM-3T) and osimertinib mutations common between three subclones (OSM-TRPL).
    Figure Legend Snippet: Development of recurrent mutations after drug treatments. A. The number of mutations in three parallel subclones following development of resistance to Dox. The number of mutations common to all three subclones (red), common to two out of three subclones (green) and mutations unique for each subclone (blue). B. A scheme showing that generation of mutations common between clones cannot occur during the propagation of the parental clone. See explanation in the text. C.Example of the lack of enrichment of mutations in open chromatin. Open chromatin assessed by ATACseq is shown in the lane with blue peaks, positions of mutations are shown in the lane with red bars. Data analysis in this experiment is shown in Table S2. C. Overlap of mutations between GDR and Lorlatinib. D. Overlap of mutations between osimertinib and Doxorubicin. E. Overlap of mutations between two independent lorlatinib-treated samples and one crizotinib-treated sample. F. Computer simulation of random generation of osimertinib-induced mutations. Observed number of common mutations is shown as red line. Random sampling of mutations and their overlap (100,000 pairs) is shown as blue lines. G. Overlap of mutations between osimertinib day 21 (0SM-3T) and osimertinib subclone 1 samples (OSM-1CL). H. Overlap of mutations between osimertinib day 21 (0SM-3T) and osimertinib mutations common between three subclones (OSM-TRPL).

    Techniques Used: Clone Assay, Sampling



    Similar Products

    atac sequencing atacseq  (Zymo Research)
    95
    Zymo Research atac sequencing atacseq
    Development of recurrent mutations after drug treatments. A. The number of mutations in three parallel subclones following development of resistance to Dox. The number of mutations common to all three subclones (red), common to two out of three subclones (green) and mutations unique for each subclone (blue). B. A scheme showing that generation of mutations common between clones cannot occur during the propagation of the parental clone. See explanation in the text. C.Example of the lack of enrichment of mutations in open chromatin. Open chromatin assessed by <t>ATACseq</t> is shown in the lane with blue peaks, positions of mutations are shown in the lane with red bars. Data analysis in this experiment is shown in Table S2. C. Overlap of mutations between GDR and Lorlatinib. D. Overlap of mutations between osimertinib and Doxorubicin. E. Overlap of mutations between two independent lorlatinib-treated samples and one crizotinib-treated sample. F. Computer simulation of random generation of osimertinib-induced mutations. Observed number of common mutations is shown as red line. Random sampling of mutations and their overlap (100,000 pairs) is shown as blue lines. G. Overlap of mutations between osimertinib day 21 (0SM-3T) and osimertinib subclone 1 samples (OSM-1CL). H. Overlap of mutations between osimertinib day 21 (0SM-3T) and osimertinib mutations common between three subclones (OSM-TRPL).
    Atac Sequencing Atacseq, supplied by Zymo Research, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/atac+sequencing+atacseq/ATAC-Seq/bio_rxiv__64898__2026__02__20__707073-327-2-8
    Average 95 stars, based on 1 article reviews
    atac sequencing atacseq - by Bioz Stars, 2026-08
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    Development of recurrent mutations after drug treatments. A. The number of mutations in three parallel subclones following development of resistance to Dox. The number of mutations common to all three subclones (red), common to two out of three subclones (green) and mutations unique for each subclone (blue). B. A scheme showing that generation of mutations common between clones cannot occur during the propagation of the parental clone. See explanation in the text. C.Example of the lack of enrichment of mutations in open chromatin. Open chromatin assessed by ATACseq is shown in the lane with blue peaks, positions of mutations are shown in the lane with red bars. Data analysis in this experiment is shown in Table S2. C. Overlap of mutations between GDR and Lorlatinib. D. Overlap of mutations between osimertinib and Doxorubicin. E. Overlap of mutations between two independent lorlatinib-treated samples and one crizotinib-treated sample. F. Computer simulation of random generation of osimertinib-induced mutations. Observed number of common mutations is shown as red line. Random sampling of mutations and their overlap (100,000 pairs) is shown as blue lines. G. Overlap of mutations between osimertinib day 21 (0SM-3T) and osimertinib subclone 1 samples (OSM-1CL). H. Overlap of mutations between osimertinib day 21 (0SM-3T) and osimertinib mutations common between three subclones (OSM-TRPL).

    Journal: bioRxiv

    Article Title: Mega-frequency mutagenesis: generation of non-random precise mutations with extremely high frequency upon adaptation of cancer cells to drugs and stress

    doi: 10.64898/2026.02.20.707073

    Figure Lengend Snippet: Development of recurrent mutations after drug treatments. A. The number of mutations in three parallel subclones following development of resistance to Dox. The number of mutations common to all three subclones (red), common to two out of three subclones (green) and mutations unique for each subclone (blue). B. A scheme showing that generation of mutations common between clones cannot occur during the propagation of the parental clone. See explanation in the text. C.Example of the lack of enrichment of mutations in open chromatin. Open chromatin assessed by ATACseq is shown in the lane with blue peaks, positions of mutations are shown in the lane with red bars. Data analysis in this experiment is shown in Table S2. C. Overlap of mutations between GDR and Lorlatinib. D. Overlap of mutations between osimertinib and Doxorubicin. E. Overlap of mutations between two independent lorlatinib-treated samples and one crizotinib-treated sample. F. Computer simulation of random generation of osimertinib-induced mutations. Observed number of common mutations is shown as red line. Random sampling of mutations and their overlap (100,000 pairs) is shown as blue lines. G. Overlap of mutations between osimertinib day 21 (0SM-3T) and osimertinib subclone 1 samples (OSM-1CL). H. Overlap of mutations between osimertinib day 21 (0SM-3T) and osimertinib mutations common between three subclones (OSM-TRPL).

    Article Snippet: Samples for ATAC sequencing (ATACseq) were prepared using Zymo-Seq ATAC Library Kit (Cat#D5458) following the manufacturer protocol.

    Techniques: Clone Assay, Sampling